Equally, treatment with the NRP2-specific mAb N2E4 inhibited pancreatic ductal adenocarcinoma cell tumor growth and metastasis by blocking interactions with β1 integrin to inhibit FAK/Erk/HIF1α/VEGF-A165 signaling (64). Here, NRP2 is linked to pancreatic ductal adenocarcinoma.